PLX

Protalix BioTherapeutics, Inc. (PLX) | Rumor.io

Protalix BioTherapeutics

PLX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,657

Bullish sentiment (50-day avg)85%

Price to earnings ratio11.7

Market capitalization216.7M

Earnings per share0.23

Dividend yield (TTM)—

Revenue (annual)52.7M

Net income (annual)-6.6M

Social

What share of all stock conversation is about PLX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% 0	0% 0

Aug 14

The stock price of Protalix BioTherapeutics, Inc. (PLX) has not returned to its pre-FDA approval level of $3.38, despite the approval being announced.
The company has managed to be profitable without a partnership, and is doing a Phase 2 trial for its gout drug.
The company has collected $14.9 million from Chiesi and $1.5 million from Pfizer, which contradicts a Zacks Research Report's projection of revenue.

Generated by AI

Sentiment

Of the messages about PLX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +8.33	89.87% +6.72	85.83% -2.6
Bearish	—	0% -8.33	10.13% -6.72	14.17% +2.6

Bullish· Aug 12

The company has reported strong Q2 results, with revenues of $19.9mm and a net income of $3.8mm, driven by the success of Elfabrio.
The balance sheet and cash position have been strengthened, with cash and equivalents up to $27.4M and total current assets reaching $92.2M, covering the company's needs for at least 12 months.
The company's pipeline and product sales are showing promise, with the Elfabrio product sales continuing to grow, and the new U.S. patent for PRX-115 issued, providing a potential boost to future revenue.

Bearish· May 13

$PLX's slow Chiesi product sales growth is a concern, with Q1 2026 sales of only $3.5M, a small increase from Q1 2025.
The company's reliance on a single product and slow sales growth makes it "uninvestable" and increases the risk of dilution or debt.
Protalix's Q1 2026 revenue of $7.4M is a red flag, worse than Q4, and raises concerns about the company's ability to meet its sales targets.

Generated by AI

Topics

Of the messages about PLX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	68.75%	23.96%
Technical Analysis	—	0%	6.25%	24.55%
Analysts	—	0%	25%	25.39%
Earnings	—	0%	0%	1.6%
Controversies	—	0%	0%	0.36%
Macro	—	0%	0%	24.15%

Earnings· May 9

$PLX stock is down despite beating expectations and seeing a 53% increase in new revenue.
The company's Q1 2018 earnings report has been released, with a transcript available for review.
The latest earnings news from $PLX is generating discussion among investors.

Announcements· Aug 7

Protalix BioTherapeutics, Inc. (PLX) reported a 344% increase in revenue to $15.1 million in Q2 2023, driven primarily by $11.7 million in sales to Chiesi following FDA and EMA approvals of Elfabrio.
The company recorded revenues from license and R&D services of $20.0 million in Q2 2023, a 270% increase from $5.4 million in Q2 2022.
Protalix BioTherapeutics' cash and cash equivalents were approximately $48.2 million at June 30, 2023, with a net revenue of $19.3 million from the first sales of Elfabrio.

Technical Analysis· Apr 4

The technical analysis of PLX stock suggests a potential breakout above $1.75 resistance, with a possible target of $2.
The stock has been trading on lower trendline support, making it a potential place to buy for a reversal with a stop loss.
PLX stock is showing signs of a flat top break potential, with a possible pop in price after lunch.

Generated by AI

Community

Of the messages about PLX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	91.49%	91.59%	74.06%
Newcomers	0%	8.51%	8.41%	25.94%

Regulars· Aug 14

The stock price of Protalix BioTherapeutics, Inc. (PLX) has not recovered from the FDA approval announcement, currently trading at a lower price than before the approval.
The company has been profitable without a partnership, conducting a Phase 2 trial for a gout drug, and inventory and accounts receivable suggest that bigger earnings are coming.
The stock price has been range-bound between $2.20 and $3, with some participants expecting a potential pop to $2.50, while others are concerned about the lack of fresh patient testimonials and the need for a reimbursement and discounting program.

Newcomers· Apr 5

The BALANCE pivotal Phase III clinical trial of PRX–102 for the treatment of Fabry disease showed positive topline results, with Protalix BioTherapeutics and Chiesa Global Rare Diseases announcing the trial's success.
If $PLX breaks through the $2 level, the next target is $3, according to one post, which also notes that the stock has already popped 5.2% and has a float of 37.7 million shares.
The stock rallied to reach $1.49 per share at the close, but inevitably fell in the after-hours, with one post noting that the surge was followed by a downfall.

Generated by AI

News

Protalix at Morgan Stanley conference: rare-disease growth in focus

13d agoInvesting.com

Wall Street Analysts Are Bullish on Top Healthcare Picks

Detailed price information for Protalix Biotherapeutics (PLX-A) from The Globe and Mail including charting and trades.

19d agoThe Globe and Mail

Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences

Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that Gilad Mamlok, Senior Vice President and Chief Financial Officer, is scheduled to participate in the following two upcoming investor conferences in New York City, New York:

22d agoYahoo Finance

Protalix Biotherapeutics Earnings Call Signals Strong Momentum

Detailed price information for Protalix Biotherapeutics (PLX-A) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Protalix (PLX) Q2 2026 Earnings Call Transcript

Motley Fool Press Release.

1mo agoThe Globe and Mail

Protalix BioTherapeutics, Inc. Q2 2026 Earnings Call Summary

Moby summary of Protalix BioTherapeutics, Inc.'s Q2 2026 earnings call

1mo agoYahoo Finance

Also Discussed

Investors talking about PLX also mention

#	Name	Attention
1	BioLine RX LtdBLRX	0%0
2	Ardelyx IncARDX	0.01%+0.01
3	Vericel CorporationVCEL	0%0
4	Daré Bioscience, Inc.DARE	0%0
5	Xtant Medical Holdings Inc.XTNT	0%0
6	Pulmatrix Inc.PULM	0%0
7	SCYNEXIS, Inc. Common StockSCYX	0%-0.02
8	MediWound Ltd.MDWD	0%0
9	FOLD - Amicus Therapeutics, Inc.	——
10	AB Corporate Bond ETFEYEG	0%0

Protalix BioTherapeutics, Inc.

Healthcare
Biotechnology

Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on developing, producing, and commercializing recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based expression system. The company’s current portfolio centers on treatments for rare diseases, including Elelyso for Gaucher disease and Elfabrio for adult patients with Fabry disease. Protalix also advances a pipeline of plant cell-expressed candidates such as PRX-115 for gout and PRX-119 for NETs-related diseases, reflecting its emphasis on enzyme replacement therapies and other biologic approaches for conditions with limited treatment options. Based in Karmiel, Israel, Protalix serves global markets through product commercialization and partnership-based development across its specialty biopharmaceutical programs.

Website

Location

2 University Plaza

Hackensack, NJ, 07601

United States

Social

What share of all stock conversation is about PLX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% 0	0% 0

Aug 14

The stock price of Protalix BioTherapeutics, Inc. (PLX) has not returned to its pre-FDA approval level of $3.38, despite the approval being announced.
The company has managed to be profitable without a partnership, and is doing a Phase 2 trial for its gout drug.
The company has collected $14.9 million from Chiesi and $1.5 million from Pfizer, which contradicts a Zacks Research Report's projection of revenue.

Generated by AI

Sentiment

Of the messages about PLX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +8.33	89.87% +6.72	85.83% -2.6
Bearish	—	0% -8.33	10.13% -6.72	14.17% +2.6

Bullish· Aug 12

The company has reported strong Q2 results, with revenues of $19.9mm and a net income of $3.8mm, driven by the success of Elfabrio.
The balance sheet and cash position have been strengthened, with cash and equivalents up to $27.4M and total current assets reaching $92.2M, covering the company's needs for at least 12 months.
The company's pipeline and product sales are showing promise, with the Elfabrio product sales continuing to grow, and the new U.S. patent for PRX-115 issued, providing a potential boost to future revenue.

Bearish· May 13

$PLX's slow Chiesi product sales growth is a concern, with Q1 2026 sales of only $3.5M, a small increase from Q1 2025.
The company's reliance on a single product and slow sales growth makes it "uninvestable" and increases the risk of dilution or debt.
Protalix's Q1 2026 revenue of $7.4M is a red flag, worse than Q4, and raises concerns about the company's ability to meet its sales targets.

Generated by AI

Topics

Of the messages about PLX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	68.75%	23.96%
Technical Analysis	—	0%	6.25%	24.55%
Analysts	—	0%	25%	25.39%
Earnings	—	0%	0%	1.6%
Controversies	—	0%	0%	0.36%
Macro	—	0%	0%	24.15%

Earnings· May 9

$PLX stock is down despite beating expectations and seeing a 53% increase in new revenue.
The company's Q1 2018 earnings report has been released, with a transcript available for review.
The latest earnings news from $PLX is generating discussion among investors.

Announcements· Aug 7

Protalix BioTherapeutics, Inc. (PLX) reported a 344% increase in revenue to $15.1 million in Q2 2023, driven primarily by $11.7 million in sales to Chiesi following FDA and EMA approvals of Elfabrio.
The company recorded revenues from license and R&D services of $20.0 million in Q2 2023, a 270% increase from $5.4 million in Q2 2022.
Protalix BioTherapeutics' cash and cash equivalents were approximately $48.2 million at June 30, 2023, with a net revenue of $19.3 million from the first sales of Elfabrio.

Technical Analysis· Apr 4

The technical analysis of PLX stock suggests a potential breakout above $1.75 resistance, with a possible target of $2.
The stock has been trading on lower trendline support, making it a potential place to buy for a reversal with a stop loss.
PLX stock is showing signs of a flat top break potential, with a possible pop in price after lunch.

Generated by AI

Community

Of the messages about PLX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	91.49%	91.59%	74.06%
Newcomers	0%	8.51%	8.41%	25.94%

Regulars· Aug 14

The stock price of Protalix BioTherapeutics, Inc. (PLX) has not recovered from the FDA approval announcement, currently trading at a lower price than before the approval.
The company has been profitable without a partnership, conducting a Phase 2 trial for a gout drug, and inventory and accounts receivable suggest that bigger earnings are coming.
The stock price has been range-bound between $2.20 and $3, with some participants expecting a potential pop to $2.50, while others are concerned about the lack of fresh patient testimonials and the need for a reimbursement and discounting program.

Newcomers· Apr 5

The BALANCE pivotal Phase III clinical trial of PRX–102 for the treatment of Fabry disease showed positive topline results, with Protalix BioTherapeutics and Chiesa Global Rare Diseases announcing the trial's success.
If $PLX breaks through the $2 level, the next target is $3, according to one post, which also notes that the stock has already popped 5.2% and has a float of 37.7 million shares.
The stock rallied to reach $1.49 per share at the close, but inevitably fell in the after-hours, with one post noting that the surge was followed by a downfall.

Generated by AI

Protalix BioTherapeutics

Social

Aug 14

Bullish· Aug 12

Bearish· May 13

Earnings· May 9

Announcements· Aug 7

Technical Analysis· Apr 4

Regulars· Aug 14

Newcomers· Apr 5

Protalix at Morgan Stanley conference: rare-disease growth in focus

Wall Street Analysts Are Bullish on Top Healthcare Picks

Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences

Protalix Biotherapeutics Earnings Call Signals Strong Momentum

Protalix (PLX) Q2 2026 Earnings Call Transcript

Protalix BioTherapeutics, Inc. Q2 2026 Earnings Call Summary

Also Discussed

Protalix BioTherapeutics, Inc.

Company Information

Location

Protalix at Morgan Stanley conference: rare-disease growth in focus

Wall Street Analysts Are Bullish on Top Healthcare Picks

Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences

Protalix Biotherapeutics Earnings Call Signals Strong Momentum

Protalix (PLX) Q2 2026 Earnings Call Transcript

Protalix BioTherapeutics, Inc. Q2 2026 Earnings Call Summary

Also Discussed

Social

Aug 14

Bullish· Aug 12

Bearish· May 13

Earnings· May 9

Announcements· Aug 7

Technical Analysis· Apr 4

Regulars· Aug 14

Newcomers· Apr 5